|
Post by buyitonsale on Sept 29, 2017 11:30:29 GMT -5
Only demand from patients will generate real bump in sales. 98% of patients do not know Affrezza exists.
Doctors acceptance and sales team efforts are important but not going to give us 20K patients any time soon.
US market needs DTC advertising to reach all PWD at least in select markets.
We need at least 500 NRx not 245 to start seeing decent patient retention and traction.
I hope the new label will help with starting a big digital ad campaign.
|
|
|
Post by compound26 on Sept 29, 2017 11:43:45 GMT -5
compound26 ... some valid points. I'd add in the challenge that more and more doctors offices have "no rep" policies. That works against a newcomer. And of course being a newcomer with one drug makes getting formulary placement an issue, so doctors know some of their patients can't get Afrezza at all and others will require the doc to deal with PA. It is interesting... Sports gives you 10 thumbs up. If I'd posted the exact same list of "challenges" hindering sales, I think I would have gotten attacked for "soft bashing". Sports is encourage members like me (who are relatively less productive like you and her ) to post more so that we can catch you in terms of our productivity on this board. That's sportswomenship!
|
|
|
Post by sportsrancho on Sept 29, 2017 12:11:59 GMT -5
compound26... some valid points. I'd add in the challenge that more and more doctors offices have "no rep" policies. That works against a newcomer. And of course being a newcomer with one drug makes getting formulary placement an issue, so doctors know some of their patients can't get Afrezza at all and others will require the doc to deal with PA. It is interesting... Sports gives you 10 thumbs up. If I'd posted the exact same list of "challenges" hindering sales, I think I would have gotten attacked for "soft bashing". I trust him:-) And agree with him. And am grateful for his accounting skills. I also know doctors who haven't seen reps in years. And appreciate how hard are reps have to work but feel as I always have that we need to put the most effort into telling the patients.
|
|
|
Post by compound26 on Oct 10, 2017 13:56:01 GMT -5
An update on the third quarter TRx growth rate vs 2nd quarter as of today (September 29, 2017). During the Mannkind second quarter conference call, Mannkind's Chief Commercial Officer, Patrick McCauley noted: In addition our TRx prescriptions grew 23% in the second quarter compared to the first quarter of 2017. seekingalpha.com/article/4096149-mannkinds-mnkd-ceo-michael-castagna-q2-2017-results-earnings-call-transcript?part=singleBased on the Afrezza sales data as reported by Symphony and maintained on this site, the 2nd quarter Afrezza TRx is 3,836. For the third quarter, with another week's number to be added (and assuming that week's numbers is similar to the numbers reported this morning for the last week), Mannkind looks like to be on track to hit somewhere around 4,850. That will be around a 26% growth rate in TRx vs 2nd quarter. Based on the above, it appears the growth rate of TRx in the 2nd and third quarters have been very consistent. An update on the third quarter TRx growth rate vs 2nd quarter as of October 10, 2017. Based on the Afrezza sales data as reported by Symphony and maintained on this site, the first quarter Afrezza TRx is 3,203. For the second quarter, it is 3,836. So it is a 19% growth rate in TRx vs 1st quarter. Based on the Afrezza sales data as reported by Symphony and maintained on this site, the 2nd quarter Afrezza TRx is 3,836. For the third quarter, it is 4,875. So it is a 27% growth rate in TRx vs 2nd quarter. Based on the above, it appears the growth rate of TRx in the 2nd and third quarters have been very consistent.
|
|
|
Post by compound26 on Jan 3, 2018 19:06:18 GMT -5
Something to think about:
Sanofi started marketing Afrezza right around January/February 2015. It ended its partnership with Mannkind in less than a year on January 4, 2016. Its high water weekly sales of Afrezza is $371,000.
Mannkind (with its in-house representatives, not the third-party representatives it used in the summary of 2016) started marketing Afrezza right around February 2017. As of today, January 3, 2018, it has marketed Afrezza less than one year. Its high water weekly sales of Afrezza so far is $647,000, which is about 175% of the high water sales of Sanofi.
So, little Mannkind, with about 1/7 of the financial resource (as Mike stated it), and probably 1/5 to 1/4 of the human resource (in terms of reps promoting Afrezza), in the same length of time, is doing 175% of the sales of the almighty Sanofi.
What do you think? If you are Sanofi, what will you think?
|
|
|
Post by mnholdem on Jan 3, 2018 19:13:40 GMT -5
Oh merde! Nous sommes des idiots! Merci beaucoup, Monsieur Brandicourt...
|
|
|
Post by sla55 on Jan 3, 2018 19:18:36 GMT -5
Oh merde! Nous sommes des idiots! Merci beaucoup, Monsieur Brandicourt... Couldn't have said it better myself.
|
|
|
Post by mnholdem on Jan 3, 2018 19:41:26 GMT -5
Thank you, mademoiselle! It's only been 40 years since I took French classes in school...or is that "l'ecole"?
|
|
|
Post by sla55 on Jan 3, 2018 20:14:42 GMT -5
Yes l'école is right (with an accent). A+
|
|
|
Post by me on Jan 3, 2018 21:36:01 GMT -5
Yes l'école is right (with an accent). A+ L'accent agui, n'est pas, et ne pas, "l'accent grave," oui?
|
|
|
Post by sla55 on Jan 3, 2018 21:54:30 GMT -5
Yes, l'accent aigu (et non pas l'accent grave). lol But this is really off-topic. Back to the original thread discussion. Sorry Liane!
|
|
|
Post by mytakeonit on Jan 3, 2018 22:28:30 GMT -5
For the international flavor ... l'okole is Kawaii
that's French, Hawaiian, American and Japanese ...
|
|
|
Post by kc on Jan 3, 2018 23:12:22 GMT -5
Oh merde! Nous sommes des idiots! Merci beaucoup, Monsieur Brandicourt... Brandicourt.........
|
|
|
Post by slugworth008 on Jan 4, 2018 23:02:17 GMT -5
Oh merde! Nous sommes des idiots! Merci beaucoup, Monsieur Brandicourt... Brandicourt......... Hear, hear - Absolutely !! To the guillotine with him !!
|
|
|
Post by seanismorris on Jan 4, 2018 23:44:19 GMT -5
This must be one of those “you had to be there” threads...
FYI to everyone else: Mr. Brandicourt is Sanofi’s CEO.
Personally I think he might have done us a favor (long term) for ending the Partnership.
For any financial losses, I blame MannKind’s management not Sanofi’s.
They took to long to get use where we are now. Hopefully they have the team together (now) to get MannKind to profitability.
This year please!
|
|